Description:
The goal of this randomized treatment de-escalation study is to formally compare outcomes in
HPV related oropharyngeal cancer tumors treated with a primary radiotherapy versus a primary
surgical approach, to provide a high level of evidence to guide the selection of treatment
options for a subsequent phase III trial
Title
- Brief Title: Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer
- Official Title: A Randomized Trial of Treatment De-Escalation for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs. Trans-Oral Surgery (ORATOR II)
Clinical Trial IDs
- ORG STUDY ID:
ORATOR2
- NCT ID:
NCT03210103
Conditions
Purpose
The goal of this randomized treatment de-escalation study is to formally compare outcomes in
HPV related oropharyngeal cancer tumors treated with a primary radiotherapy versus a primary
surgical approach, to provide a high level of evidence to guide the selection of treatment
options for a subsequent phase III trial
Detailed Description
The goal of this randomized treatment de-escalation study is to formally compare outcomes in
HPV related oropharyngeal cancer tumors treated with a primary radiotherapy versus a primary
surgical approach, to provide a high level of evidence to guide the selection of treatment
options for a subsequent phase III trial
The study will compare overall survival rates relative to historical controls for
de-intensified primary radiotherapy [60 GY +/- chemotherapy] versus transoral surgery (TOS)
and neck dissection [+/- adjuvant 50Gy radiotherapy] in patients with early T-stage
HPV-positive squamous cell carcinoma of the oropharynx and to compare quality of life (QOL)
profiles.
The study will require a sample size of 140 patients randomized in a 1:1 ratio between the
two arms. Arm 1 (radiotherapy +/1 chemotherapy) and Arm 2 (TOS)
Patients will be followed for a total of 5 years
Trial Arms
Name | Type | Description | Interventions |
---|
Arm 1, Radiation +/- Chemotherapy | Active Comparator | Standard Treatment (Radiation +/- Chemotherapy) | |
Arm 2, TOS + Neck Dissection | Experimental | Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required) | |
Eligibility Criteria
Inclusion Criteria:
- Age 18 years or older
- willing to provide informed consent
- ECOG performance status 0-2
- Histologically confirmed squamous cell carcinoma
- P16 positive, or HPV positive
- Primary tumor site in the oropharynx (includes tonsil, soft palate, base of tongue,
walls of oropharynx)
- Eligible for curative intent treatment, with likely negative resection margins at
surgery. For patients where adequate transoral access is in question, they will first
undergo an examination under anesthesia prior to randomization to ensure adequate
exposure can be obtained.
- Smokers and non-smokers are included. Patients will be stratified by ,<10 pack years
smoking history versus > or equal to 10 pack years.
- Tumor stage (AJCC 8th edition): T1 or T2
- Nodal stage (AJCC 8th edition): N0, N1, or N2
- For patients who may require chemotherapy (ie, patients with multiple lymph nodes
positive or a single node more than 3 cm in size, in any plane, CBC/differential
within 4 weeks prior to randomization with adequate bone marrow function, hepatic, and
renal function defined as: Hemoglobin ≥ 80 g/L; Absolute neutrophil count ≥ 1.5 x 10
9/L, platelets ≥ 100 x 10 9/L, bilirubin ≤ 35 umol/L, AST or ALT ≤ 3 x the upper limit
of normal; serum creatinine ≤ 130 umol/L or creatinine clearance ≥ 50 ml/min
- patients assessed at head and neck multidisciplinary clinic (with assessment by
radiation oncologist and surgeon) and presented at multidisciplinary tumor board prior
to randomization
Exclusion Criteria:
- unambiguous clinical or radiological evidence of extranodaal extension on
pre-treatment imaging. This includes the presence of matted notes, defined as 3 or
more nodes that are abutting with loss of intervening fat planes
- Serious medical comorbidities or other contraindications to radiotherapy, chemotherapy
or surgery
- prior history of head and neck cancer within 5 years
- prior head and neck radiation at any time
- metastatic disease
- inability to attend full course of radiotherapy or follow up visits
- prior invasive malignant disease unless disease-free for at least 5 years or more,
with the exception of non-melanoma skin cancer
- pregnant or lactating women
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Overall Survival |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Time from randomization to death from any cause |
Secondary Outcome Measures
Measure: | Quality of Life 1 year post treatment |
Time Frame: | 1 year post treatment |
Safety Issue: | |
Description: | Quality of life 1 year post treatment as assessed with the MD Anderson Dysphagia Inventory (MDADI) |
Measure: | Progression free survival comparison with historical controls |
Time Frame: | 5 years |
Safety Issue: | |
Description: | Defined as time from randomization to death from any cause |
Measure: | Quality of life |
Time Frame: | Baseline to 5 years follow up |
Safety Issue: | |
Description: | Quality of Life using the following questionnaire: MD Anderson Dysphagia Inventory (MDADI) |
Measure: | Quality of life |
Time Frame: | Baseline to 5 years follow up |
Safety Issue: | |
Description: | Quality of Life using the following questionnaire: EORTC QLQ C30 |
Measure: | Quality of life |
Time Frame: | Baseline to 5 years follow up |
Safety Issue: | |
Description: | Quality of Life using the following questionnaire: H&N35 scale |
Measure: | Quality of life |
Time Frame: | Baseline to 5 years follow up |
Safety Issue: | |
Description: | Quality of Life using the following questionnaire: Voice Handicap Index (VHI-10) |
Measure: | Quality of life |
Time Frame: | Baseline to 5 years follow up |
Safety Issue: | |
Description: | Quality of Life using the following questionnaire: Neck Dissection Impairment Index (NDII) |
Measure: | Quality of life |
Time Frame: | Baseline to 5 years follow up |
Safety Issue: | |
Description: | Quality of Life using the following questionnaire: Patient Neurotoxicity Questionnaire (PNQ) |
Measure: | toxicity profile of both study arms using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 4 |
Time Frame: | Randomization until 5 years follow up |
Safety Issue: | |
Description: | To determine to toxicity profile of both study arms using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 4 |
Measure: | Feeding tube rate at 1 year |
Time Frame: | baseline to 1 year post treatment |
Safety Issue: | |
Description: | Measure other functional measurements such as feeding tube rate at 1 year |
Measure: | CTCAE Dysphagia grade |
Time Frame: | baseline to 5 years post treatment |
Safety Issue: | |
Description: | Measure other functional measurements such as CTCAE Dysphagia grade |
Measure: | Speech intelligibility |
Time Frame: | baseline to 5 years post treatment |
Safety Issue: | |
Description: | Measure other functional measurements such as speech intelligibility |
Measure: | Normalcy of diet |
Time Frame: | baseline to 5 years post treatment |
Safety Issue: | |
Description: | Measure other functional measurements such as normalcy of diet |
Measure: | 2 year progression-free survival comparison between Arm 1 and Arm 2 |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Time from randomization to disease progress at any site or death from any cause |
Details
Phase: | N/A |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Lawson Health Research Institute |
Trial Keywords
- Transoral Surgery
- Head and Neck Cancer
Last Updated
June 11, 2021